EdiGene, Immunochina to develop CAR-T therapy

By The Science Advisory Board staff writers

May 27, 2020 -- EdiGene and Immunochina have announced they are collaborating on the development of allogeneic CAR-T therapy for cancer.

Both companies have experience in late-stage hematological malignancies. Though strides have been made in the use of autologous T-cell therapies, they believe allogeneic T cells could also play an important role in future treatments, according to the companies.

No other details about the partnership were provided.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.